Galderma stock costs EUR 177.03 at CHF 38.4 billion market value

Published on 10/09/2026 at 15:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galderma stock was EUR 177.03 on October 9, 2026 versus EUR 175.33. Market value was CHF 38.4 billion and P/E stood at 48.55 today.

Key points in brief

Galderma stock was EUR 177.03 at Lang & Schwarz on October 9, 2026, versus a prior close of EUR 175.33.
Galderma had a CHF 38.4 billion market value and a P/E ratio of 48.55.
The SIX price was 12.51 percent below its CHF 188.25 52-week high on October 9, 2026.
An analyst fair value of CHF 197.55 stood 19.95 percent above the SIX price, according to an October 1 update.
Galderma's Q3 2026 sales and revenue release is scheduled for October 21, 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma stock (ISIN CH1335392721) was trading at EUR 177.03 at Lang & Schwarz on October 9, 2026 at 3:35 p.m. CEST. The price was plus 0.97 percent versus the EUR 175.33 prior close, while Galderma's market value stood at CHF 38.4 billion and its P/E ratio was 48.55.

Trading stays below the yearly high

On the SIX Swiss Exchange, Galderma was last at CHF 164.70 on October 9, 2026 at 3:25 p.m. CEST. The quote was 12.51 percent below the CHF 188.25 52-week high and 22.27 percent above the CHF 134.70 low.

Trading volume reached 104,245 shares against an average volume of 546,089. That places activity at 80.88 percent below the average, making turnover a material part of the day's market picture.

Valuation carries a clear comparison

Galderma's CHF 164.70 SIX price also sits below the CHF 197.55 fair value cited in an October 1 update by Simply Wall Street. The target lies 19.95 percent above that SIX price, while the finance quote gives Galderma a P/E ratio of 48.55.

Boursorama reported on September 21, 2026 that Galderma had joined the SMI. The index membership gives the stock a larger benchmark context without changing the separate SIX and Lang & Schwarz price references.

Comparison with peers

Galderma: plus 0.97 percent, P/E 48.55, market capitalization CHF 38.4 billion

AbbVie (NYSE, USD): plus 0.71 percent, P/E 77.35, market capitalization USD 484.7 billion

SMI (Switzerland): plus 1.19 percent, P/E, market capitalization

Next company date

The next dated company item is a Q3 2026 sales and revenue release scheduled for October 21, 2026, according to MarketScreener. For the market, that date is the next defined point at which operating performance can be compared with the current valuation.

Galderma price and quote

At Lang & Schwarz, Galderma was trading at EUR 177.03 on October 9, 2026 at 3:35 p.m. CEST, with a change of plus 0.97 percent versus the EUR 175.33 prior close from October 8, 2026. On the SIX, the stock was last at CHF 164.70 at 3:25 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Galderma stock.